In the studies, the Merck immunotherapy extended survival for advanced lung cancer and stomach cancer patients with high PD-L1 expression.
The diagnostic can now be used to identify a wider range of patients with stage III or metastatic NSCLC who may benefit from first-line treatment with Keytruda.
A phylogenetic analysis that included multiple samples per patient suggests overlapping driver mutations make their way into multiple metastases in each patient.
Physicians can now use the Dako PD-L1 IHC 22C3 pharmDx assay to identify urothelial carcinoma patients who may benefit from the anti-PD1 immunotherapy.
An international team of researchers also suggested that MUC16 mutations could identify patients who might benefit from immunotherapy treatment.
A Samsung University team found that mutation load measured with the Guardant360 liquid biopsy assay predicted response as well as tissue-based TMB.
Patients with PD-L1-expressing gastric or gastroesophageal junction tumors can now be identified for potential treatment with Keytruda using Agilent's assay.